Of @,@ patients ( FREEDOMS ITT population ) , @,@ were eligible , and @ enrolled in the extension study ( continuous-fingolimod : @ mg -LSB- n = @ -RSB- , @ mg -LSB- n = @ -RSB- ; placebo-fingolimod : @ mg -LSB- n = @ -RSB- , @ mg -LSB- n = @ -RSB- ) ; @ formed the extension ITT population ( n = @ ; n = @ ; n = @ ; n = @ ) and @ ( @ % ) completed .